nach oben

International Journal of Clinical Oncology

Erschienen in:

01.04.2011 | Review Article

Proteomic analysis of soft tissue sarcoma

verfasst von: Yoshiyuki Suehara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Soft tissue sarcomas are a heterogeneous group of malignant mesenchymal tumors, and novel tumors biomarkers and therapeutic targets are required to achieve early diagnosis and optimize therapy for individual patients. Global protein expression studies, an approach known as “proteomics”, can offer important clues for understanding tumor biology that cannot be obtained by other approaches. Proteomic studies, such as two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry, have provided protein expression profiles of soft tissue tumors that can be used to develop novel diagnostic and therapeutic biomarkers and allow molecular classification of tumors. In this article, a brief description of the methodology will be provided, followed by a few examples of the recent proteomic studies that have generated new information for the diagnosis, classification and treatment of soft tissue tumors.

Fletcher CDM, Unni KK, Mertens F (2002) World health organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon

Tschoep K, Kohlmann A, Schlemmer M et al (2007) Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63:111–124PubMedCrossRef

Francis P, Namlos HM, Muller C et al (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73PubMedCrossRef

Allander SV, Illei PB, Chen Y et al (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161:1587–1595PubMedCrossRef

Nakagawa Y, Numoto K, Yoshida A et al (2006) Chromosomal and genetic imbalances in synovial sarcoma detected by conventional and microarray comparative genomic hybridization. J Cancer Res Clin Oncol 132:444–450PubMedCrossRef

Lee YF, John M, Falconer A et al (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 64:7201–7204PubMedCrossRef

Nielsen TO, West RB, Linn SC et al (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301–1307PubMedCrossRef

Nagayama S, Katagiri T, Tsunoda T et al (2002) Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62:5859–5866PubMed

Nakayama R, Mitani S, Nakagawa T et al (2010) Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol 34:1599–1607PubMed

10.

Antonescu CR (2008) Molecular profiling in the diagnosis and treatment of high grade sarcomas. Ultrastruct Pathol 32:37–42PubMedCrossRef

11.

Kawai A, Kondo T, Suehara Y et al (2008) Global protein-expression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res 466:2099–2106PubMedCrossRef

12.

Nielsen TO (2006) Microarray analysis of sarcomas. Adv Anat Pathol 13:166–173PubMedCrossRef

13.

Suehara Y, Kondo T, Fujii K et al (2006) Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics 6:4402–4409PubMedCrossRef

14.

Gygi SP, Rochon Y, Franza BR et al (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19:1720–1730PubMed

15.

Chen G, Gharib TG, Huang CC et al (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1:304–313PubMedCrossRef

16.

Yanagisawa K, Shyr Y, Xu BJ et al (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433–439PubMedCrossRef

17.

Alaiya AA, Franzen B, Hagman A et al (2002) Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer 98:895–899PubMedCrossRef

18.

Reyzer ML, Caldwell RL, Dugger TC et al (2004) Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 64:9093–9100PubMedCrossRef

19.

Cui JW, Wang J, He K et al (2004) Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 10:6887–6896PubMedCrossRef

20.

Varambally S, Yu J, Laxman B et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393–406PubMedCrossRef

21.

Suehara Y, Kikuta K, Nakayama R et al (2010) GST-P1 as a histological biomarker of synovial sarcoma revealed by proteomics. Proteomics Clin Appl 3:623–634CrossRef

22.

Suehara Y, Kikuta K, Nakayama R et al (2010) Anatomic site-specific proteomic signatures of gastrointestinal stromal tumors. Proteomics Clin Appl 3:584–596CrossRef

23.

Takahashi T, Naka T, Fujimoto M et al (2008) Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumors. Proteomics Clin Appl 2:1246–1254PubMedCrossRef

24.

Li Y, Liang Q, Wen YQ et al (2010) Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet 198:97–106PubMedCrossRef

25.

Li Y, Dang TA, Shen J et al (2006) Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 6:3426–3435PubMedCrossRef

26.

Fetsch PA, Simone NL, Bryant-Greenwood PK et al (2002) Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol 118:870–876PubMedCrossRef

27.

Kikuta K, Tochigi N, Shimoda T et al (2009) Nucleophosmin as a candidate prognostic biomarker of Ewing’s sarcoma revealed by proteomics. Clin Cancer Res 15:2885–2894PubMedCrossRef

28.

Suehara Y, Kondo T, Seki K et al (2008) Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 14:1707–1717PubMedCrossRef

29.

Holt GE, Schwartz HS, Caldwell RL (2006) Proteomic profiling in musculoskeletal oncology by MALDI mass spectrometry. Clin Orthop Relat Res 450:105–110PubMedCrossRef

30.

Suehara Y, Tochigi N, Kubota D et al (2011) Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics (in press)

31.

Kang HJ, Koh KH, Yang E et al (2006) Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations. Proteomics 6:1151–1157PubMedCrossRef

32.

Kikuta K, Tochigi N, Saito S et al (2010) Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl 4:560–567PubMed

33.

Conrad DH, Goyette J, Thomas PS (2008) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23(Suppl 1):78–84PubMedCrossRef

34.

Alessandro R, Fontana S, Kohn E et al (2005) Proteomic strategies and their application in cancer research. Tumori 91:447–455PubMed

35.

Granville CA, Dennis PA (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32:169–176PubMedCrossRef

36.

Kondo T, Hirohashi S (2006) Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 1:2940–2956PubMedCrossRef

37.

Kondo T, Hirohashi S (2009) Application of 2D-DIGE in cancer proteomics toward personalized medicine. Methods Mol Biol 577:135–154PubMedCrossRef

38.

Nakayama R, Nemoto T, Takahashi H et al (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749–759PubMedCrossRef

39.

Suda T, Tsunoda T, Uchida N et al (2006) Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci 97:411–419PubMedCrossRef

40.

Ueda T, Aozasa K, Tsujimoto M et al (1988) Prognostic significance of mast cells in soft tissue sarcoma. Cancer 62:2416–2419PubMedCrossRef

41.

Oda Y, Hashimoto H, Tsuneyoshi M et al (1993) Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol 17:35–44PubMedCrossRef

42.

Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMedCrossRef

43.

van der Zwan SM, DeMatteo RP (2005) Gastrointestinal stromal tumor: 5 years later. Cancer 104:1781–1788PubMedCrossRef

44.

Kang HJ, Nam SW, Kim H et al (2005) Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24:1066–1074PubMedCrossRef

45.

Antonescu CR, Viale A, Sarran L et al (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10:3282–3290PubMedCrossRef

46.

El-Rifai W, Sarlomo-Rikala M, Andersson LC et al (2000) DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 60:3899–3903PubMed

47.

Pruneri G, Mazzarol G, Fabris S et al (2003) Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol 16:886–892PubMedCrossRef

48.

Koon N, Schneider-Stock R, Sarlomo-Rikala M et al (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235–240PubMedCrossRef

49.

Kikuta K, Gotoh M, Kanda T et al (2009) Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol 40:60–72

50.

Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625PubMedCrossRef

51.

Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632PubMedCrossRef

52.

Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRef

53.

Resendes BL, Kuo SF, Robertson NG et al (2004) Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol 5:185–202PubMed

Titel: Proteomic analysis of soft tissue sarcoma
verfasst von: Yoshiyuki Suehara
Publikationsdatum: 01.04.2011
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2011
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0203-9

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Proteomic analysis of soft tissue sarcoma

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Full-thickness chest-wall resection followed by thorax reconstruction for recurrent malignant phyllodes tumor

Spindle cell carcinoma of the nasal cavity

Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis

Questionnaire survey of the current status of radical trachelectomy in Japan

Basic science and clinical frontiers of sarcoma treatment

An inconspicuous fallopian-tube carcinoma clinically manifested as a rectovaginal septal tumor: a pitfall for diagnosis and treatment

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie